The global COX-2 Selective NSAIDs market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on COX-2 Selective NSAIDs competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.

Nonsteroidal anti-inflammatory drugs (NSAIDs) have analgesic, antipyretic and anti-inflammatory effects, but can also cause a series of adverse reactions. Their mechanism of action is mainly to inhibit cyclooxygenase [cyclooxygenase, COX; also known as prostaglandin synthase (PGHS)], preventing the conversion of arachidonic acid into various prostaglandins, prostacyclins and thromboxanes. COX has two isoenzymes, COX-1 and COX-2, and there are significant differences in the regulation and expression of the two in different tissues. Various NSAIDs have different enzyme inhibition abilities, which can affect their activity and toxicity at the same time. Before the discovery of the COX-2 isoenzyme in the early 1990s, most NSAIDs could effectively inhibit both COXs. However, researchers later developed NSAIDs that can preferentially inhibit COX-2 while retaining the activity of COX-1. COX-2 is in the inflammatory mediators and participates in the production of inflammatory mediators, while COX-1 has an important gastric cell protective effect. The new drugs are called COX-2 selective NSAIDs (COXIBs), also known as COX-2 inhibitors and COX-2 selective inhibitors.

The North American market for COX-2 Selective NSAIDs is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.

The Asia-Pacific market for COX-2 Selective NSAIDs is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.

Major global manufacturers of COX-2 Selective NSAIDs include Pfizer, Teva, Mylan, Apotex, Lupin, Jiangsu Hengrui Medicine, Merck, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.

This report delivers a comprehensive overview of the global COX-2 Selective NSAIDs market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding COX-2 Selective NSAIDs. The COX-2 Selective NSAIDs market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global COX-2 Selective NSAIDs market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist COX-2 Selective NSAIDs manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of COX-2 Selective NSAIDs Market Report

Report Metric	Details
Report Name	COX-2 Selective NSAIDs Market
Segment by Type	Celecoxib Rofecoxib Valdecoxib Etoricoxib
by Application	Hospital Clinic Other
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Pfizer, Teva, Mylan, Apotex, Lupin, Jiangsu Hengrui Medicine, Merck
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for COX-2 Selective NSAIDs manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines COX-2 Selective NSAIDs sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

Who are the main players in the COX-2 Selective NSAIDs Market report?

Ans: The main players in the COX-2 Selective NSAIDs Market are Pfizer, Teva, Mylan, Apotex, Lupin, Jiangsu Hengrui Medicine, Merck

What are the Application segmentation covered in the COX-2 Selective NSAIDs Market report?

Ans: The Applications covered in the COX-2 Selective NSAIDs Market report are Hospital, Clinic, Other

What are the Type segmentation covered in the COX-2 Selective NSAIDs Market report?

Ans: The Types covered in the COX-2 Selective NSAIDs Market report are Celecoxib, Rofecoxib, Valdecoxib, Etoricoxib

1 COX-2 Selective NSAIDs Market Overview

1.1 Product Definition

1.2 COX-2 Selective NSAIDs by Type

1.2.1 Global COX-2 Selective NSAIDs Market Value by Type: 2025 vs 2032

1.2.2 Celecoxib

1.2.3 Rofecoxib

1.2.4 Valdecoxib

1.2.5 Etoricoxib

1.3 COX-2 Selective NSAIDs by Application

1.3.1 Global COX-2 Selective NSAIDs Market Value by Application: 2025 vs 2032

1.3.2 Hospital

1.3.3 Clinic

1.3.4 Other

1.4 Global COX-2 Selective NSAIDs Market Size Estimates and Forecasts

1.4.1 Global COX-2 Selective NSAIDs Revenue 2021–2032

1.4.2 Global COX-2 Selective NSAIDs Sales 2021–2032

1.4.3 Global COX-2 Selective NSAIDs Market Average Price (2021–2032)

1.5 Assumptions and Limitations

2 COX-2 Selective NSAIDs Market Competition by Manufacturers

2.1 Global COX-2 Selective NSAIDs Sales Market Share by Manufacturers (2021–2026)

2.2 Global COX-2 Selective NSAIDs Revenue Market Share by Manufacturers (2021–2026)

2.3 Global COX-2 Selective NSAIDs Average Price by Manufacturers (2021–2026)

2.4 Global Key Players of COX-2 Selective NSAIDs, Industry Ranking, 2023 vs 2024 vs 2025

2.5 Global Key Manufacturers of COX-2 Selective NSAIDs, Manufacturing Sites and Headquarters

2.6 Global Key Manufacturers of COX-2 Selective NSAIDs, Product Types and Applications

2.7 Global Key Manufacturers of COX-2 Selective NSAIDs, Date of Entry into the Industry

2.8 Global COX-2 Selective NSAIDs Market Competitive Situation and Trends

2.8.1 Global COX-2 Selective NSAIDs Market Concentration Rate

2.8.2 The Top 5 and Top 10 Global COX-2 Selective NSAIDs Players Market Share by Revenue

2.8.3 Global COX-2 Selective NSAIDs Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global COX-2 Selective NSAIDs Market Scenario by Region

3.1 Global COX-2 Selective NSAIDs Market Size by Region: 2021 vs 2025 vs 2032

3.2 Global COX-2 Selective NSAIDs Sales by Region: 2021–2032

3.2.1 Global COX-2 Selective NSAIDs Sales by Region: 2021–2026

3.2.2 Global COX-2 Selective NSAIDs Sales by Region: 2027–2032

3.3 Global COX-2 Selective NSAIDs Revenue by Region: 2021–2032

3.3.1 Global COX-2 Selective NSAIDs Revenue by Region: 2021–2026

3.3.2 Global COX-2 Selective NSAIDs Revenue by Region: 2027–2032

3.4 North America COX-2 Selective NSAIDs Market Facts & Figures by Country

3.4.1 North America COX-2 Selective NSAIDs Market Size by Country: 2021 vs 2025 vs 2032

3.4.2 North America COX-2 Selective NSAIDs Sales by Country (2021–2032)

3.4.3 North America COX-2 Selective NSAIDs Revenue by Country (2021–2032)

3.4.4 United States

3.4.5 Canada

3.5 Europe COX-2 Selective NSAIDs Market Facts & Figures by Country

3.5.1 Europe COX-2 Selective NSAIDs Market Size by Country: 2021 vs 2025 vs 2032

3.5.2 Europe COX-2 Selective NSAIDs Sales by Country (2021–2032)

3.5.3 Europe COX-2 Selective NSAIDs Revenue by Country (2021–2032)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific COX-2 Selective NSAIDs Market Facts & Figures by Region

3.6.1 Asia Pacific COX-2 Selective NSAIDs Market Size by Region: 2021 vs 2025 vs 2032

3.6.2 Asia Pacific COX-2 Selective NSAIDs Sales by Region (2021–2032)

3.6.3 Asia Pacific COX-2 Selective NSAIDs Revenue by Region (2021–2032)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America COX-2 Selective NSAIDs Market Facts & Figures by Country

3.7.1 Latin America COX-2 Selective NSAIDs Market Size by Country: 2021 vs 2025 vs 2032

3.7.2 Latin America COX-2 Selective NSAIDs Sales by Country (2021–2032)

3.7.3 Latin America COX-2 Selective NSAIDs Revenue by Country (2021–2032)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.7.7 Colombia

3.8 Middle East and Africa COX-2 Selective NSAIDs Market Facts & Figures by Country

3.8.1 Middle East and Africa COX-2 Selective NSAIDs Market Size by Country: 2021 vs 2025 vs 2032

3.8.2 Middle East and Africa COX-2 Selective NSAIDs Sales by Country (2021–2032)

3.8.3 Middle East and Africa COX-2 Selective NSAIDs Revenue by Country (2021–2032)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global COX-2 Selective NSAIDs Sales by Type (2021–2032)

4.1.1 Global COX-2 Selective NSAIDs Sales by Type (2021–2026)

4.1.2 Global COX-2 Selective NSAIDs Sales by Type (2027–2032)

4.1.3 Global COX-2 Selective NSAIDs Sales Market Share by Type (2021–2032)

4.2 Global COX-2 Selective NSAIDs Revenue by Type (2021–2032)

4.2.1 Global COX-2 Selective NSAIDs Revenue by Type (2021–2026)

4.2.2 Global COX-2 Selective NSAIDs Revenue by Type (2027–2032)

4.2.3 Global COX-2 Selective NSAIDs Revenue Market Share by Type (2021–2032)

4.3 Global COX-2 Selective NSAIDs Price by Type (2021–2032)

5 Segment by Application

5.1 Global COX-2 Selective NSAIDs Sales by Application (2021–2032)

5.1.1 Global COX-2 Selective NSAIDs Sales by Application (2021–2026)

5.1.2 Global COX-2 Selective NSAIDs Sales by Application (2027–2032)

5.1.3 Global COX-2 Selective NSAIDs Sales Market Share by Application (2021–2032)

5.2 Global COX-2 Selective NSAIDs Revenue by Application (2021–2032)

5.2.1 Global COX-2 Selective NSAIDs Revenue by Application (2021–2026)

5.2.2 Global COX-2 Selective NSAIDs Revenue by Application (2027–2032)

5.2.3 Global COX-2 Selective NSAIDs Revenue Market Share by Application (2021–2032)

5.3 Global COX-2 Selective NSAIDs Price by Application (2021–2032)

6 Key Companies Profiled

6.1 Pfizer

6.1.1 Pfizer Company Information

6.1.2 Pfizer Description and Business Overview

6.1.3 Pfizer COX-2 Selective NSAIDs Sales, Revenue, and Gross Margin (2021–2026)

6.1.4 Pfizer COX-2 Selective NSAIDs Product Portfolio

6.1.5 Pfizer Recent Developments/Updates

6.2 Teva

6.2.1 Teva Company Information

6.2.2 Teva Description and Business Overview

6.2.3 Teva COX-2 Selective NSAIDs Sales, Revenue, and Gross Margin (2021–2026)

6.2.4 Teva COX-2 Selective NSAIDs Product Portfolio

6.2.5 Teva Recent Developments/Updates

6.3 Mylan

6.3.1 Mylan Company Information

6.3.2 Mylan Description and Business Overview

6.3.3 Mylan COX-2 Selective NSAIDs Sales, Revenue, and Gross Margin (2021–2026)

6.3.4 Mylan COX-2 Selective NSAIDs Product Portfolio

6.3.5 Mylan Recent Developments/Updates

6.4 Apotex

6.4.1 Apotex Company Information

6.4.2 Apotex Description and Business Overview

6.4.3 Apotex COX-2 Selective NSAIDs Sales, Revenue, and Gross Margin (2021–2026)

6.4.4 Apotex COX-2 Selective NSAIDs Product Portfolio

6.4.5 Apotex Recent Developments/Updates

6.5 Lupin

6.5.1 Lupin Company Information

6.5.2 Lupin Description and Business Overview

6.5.3 Lupin COX-2 Selective NSAIDs Sales, Revenue, and Gross Margin (2021–2026)

6.5.4 Lupin COX-2 Selective NSAIDs Product Portfolio

6.5.5 Lupin Recent Developments/Updates

6.6 Jiangsu Hengrui Medicine

6.6.1 Jiangsu Hengrui Medicine Company Information

6.6.2 Jiangsu Hengrui Medicine Description and Business Overview

6.6.3 Jiangsu Hengrui Medicine COX-2 Selective NSAIDs Sales, Revenue, and Gross Margin (2021–2026)

6.6.4 Jiangsu Hengrui Medicine COX-2 Selective NSAIDs Product Portfolio

6.6.5 Jiangsu Hengrui Medicine Recent Developments/Updates

6.7 Merck

6.7.1 Merck Company Information

6.7.2 Merck Description and Business Overview

6.7.3 Merck COX-2 Selective NSAIDs Sales, Revenue, and Gross Margin (2021–2026)

6.7.4 Merck COX-2 Selective NSAIDs Product Portfolio

6.7.5 Merck Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 COX-2 Selective NSAIDs Industry Chain Analysis

7.2 COX-2 Selective NSAIDs Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 COX-2 Selective NSAIDs Production Mode & Process Analysis

7.4 COX-2 Selective NSAIDs Sales and Marketing

7.4.1 COX-2 Selective NSAIDs Sales Channels

7.4.2 COX-2 Selective NSAIDs Distributors

7.5 COX-2 Selective NSAIDs Customer Analysis

8 COX-2 Selective NSAIDs Market Dynamics

8.1 COX-2 Selective NSAIDs Industry Trends

8.2 COX-2 Selective NSAIDs Market Drivers

8.3 COX-2 Selective NSAIDs Market Challenges

8.4 COX-2 Selective NSAIDs Market Restraints

8.5 Impact of U.S. Tariffs

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Jiangsu Hengrui Medicine

Merck

List of Tables

Table 1. Global COX-2 Selective NSAIDs Market Value by Type (US$ Million), 2025 vs 2032

Table 2. Global COX-2 Selective NSAIDs Market Value by Application (US$ Million), 2025 vs 2032

Table 3. Global COX-2 Selective NSAIDs Market Competitive Situation by Manufacturers in 2025

Table 4. Global COX-2 Selective NSAIDs Sales (K Units) of Key Manufacturers (2021–2026)

Table 5. Global COX-2 Selective NSAIDs Sales Market Share by Manufacturers (2021–2026)

Table 6. Global COX-2 Selective NSAIDs Revenue (US$ Million) by Manufacturers (2021–2026)

Table 7. Global COX-2 Selective NSAIDs Revenue Share by Manufacturers (2021–2026)

Table 8. Global Market COX-2 Selective NSAIDs Average Price (US$/Unit) of Key Manufacturers (2021–2026)

Table 9. Global Key Players of COX-2 Selective NSAIDs, Industry Ranking, 2023 vs 2024 vs 2025

Table 10. Global Key Manufacturers of COX-2 Selective NSAIDs, Manufacturing Sites and Headquarters

Table 11. Global Key Manufacturers of COX-2 Selective NSAIDs, Product Types and Applications

Table 12. Global Key Manufacturers of COX-2 Selective NSAIDs, Date of Entry into the Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global COX-2 Selective NSAIDs Companies by Tier (Tier 1, Tier 2, Tier 3), based on COX-2 Selective NSAIDs Revenue, 2025

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global COX-2 Selective NSAIDs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 17. Global COX-2 Selective NSAIDs Sales by Region (K Units), 2021–2026

Table 18. Global COX-2 Selective NSAIDs Sales Market Share by Region (2021–2026)

Table 19. Global COX-2 Selective NSAIDs Sales by Region (K Units), 2027–2032

Table 20. Global COX-2 Selective NSAIDs Sales Market Share by Region (2027–2032)

Table 21. Global COX-2 Selective NSAIDs Revenue by Region (US$ Million), 2021–2026

Table 22. Global COX-2 Selective NSAIDs Revenue Market Share by Region (2021–2026)

Table 23. Global COX-2 Selective NSAIDs Revenue by Region (US$ Million), 2027–2032

Table 24. Global COX-2 Selective NSAIDs Revenue Market Share by Region (2027–2032)

Table 25. North America COX-2 Selective NSAIDs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 26. North America COX-2 Selective NSAIDs Sales by Country (K Units), 2021–2026

Table 27. North America COX-2 Selective NSAIDs Sales by Country (K Units), 2027–2032

Table 28. North America COX-2 Selective NSAIDs Revenue by Country (US$ Million), 2021–2026

Table 29. North America COX-2 Selective NSAIDs Revenue by Country (US$ Million), 2027–2032

Table 30. Europe COX-2 Selective NSAIDs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 31. Europe COX-2 Selective NSAIDs Sales by Country (K Units), 2021–2026

Table 32. Europe COX-2 Selective NSAIDs Sales by Country (K Units), 2027–2032

Table 33. Europe COX-2 Selective NSAIDs Revenue by Country (US$ Million), 2021–2026

Table 34. Europe COX-2 Selective NSAIDs Revenue by Country (US$ Million), 2027–2032

Table 35. Asia Pacific COX-2 Selective NSAIDs Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)

Table 36. Asia Pacific COX-2 Selective NSAIDs Sales by Region (K Units), 2021–2026

Table 37. Asia Pacific COX-2 Selective NSAIDs Sales by Region (K Units), 2027–2032

Table 38. Asia Pacific COX-2 Selective NSAIDs Revenue by Region (US$ Million), 2021–2026

Table 39. Asia Pacific COX-2 Selective NSAIDs Revenue by Region (US$ Million), 2027–2032

Table 40. Latin America COX-2 Selective NSAIDs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 41. Latin America COX-2 Selective NSAIDs Sales by Country (K Units), 2021–2026

Table 42. Latin America COX-2 Selective NSAIDs Sales by Country (K Units), 2027–2032

Table 43. Latin America COX-2 Selective NSAIDs Revenue by Country (US$ Million), 2021–2026

Table 44. Latin America COX-2 Selective NSAIDs Revenue by Country (US$ Million), 2027–2032

Table 45. Middle East and Africa COX-2 Selective NSAIDs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 46. Middle East and Africa COX-2 Selective NSAIDs Sales by Country (K Units), 2021–2026

Table 47. Middle East and Africa COX-2 Selective NSAIDs Sales by Country (K Units), 2027–2032

Table 48. Middle East and Africa COX-2 Selective NSAIDs Revenue by Country (US$ Million), 2021–2026

Table 49. Middle East and Africa COX-2 Selective NSAIDs Revenue by Country (US$ Million), 2027–2032

Table 50. Global COX-2 Selective NSAIDs Sales (K Units) by Type (2021–2026)

Table 51. Global COX-2 Selective NSAIDs Sales (K Units) by Type (2027–2032)

Table 52. Global COX-2 Selective NSAIDs Sales Market Share by Type (2021–2026)

Table 53. Global COX-2 Selective NSAIDs Sales Market Share by Type (2027–2032)

Table 54. Global COX-2 Selective NSAIDs Revenue (US$ Million) by Type (2021–2026)

Table 55. Global COX-2 Selective NSAIDs Revenue (US$ Million) by Type (2027–2032)

Table 56. Global COX-2 Selective NSAIDs Revenue Market Share by Type (2021–2026)

Table 57. Global COX-2 Selective NSAIDs Revenue Market Share by Type (2027–2032)

Table 58. Global COX-2 Selective NSAIDs Price (US$/Unit) by Type (2021–2026)

Table 59. Global COX-2 Selective NSAIDs Price (US$/Unit) by Type (2027–2032)

Table 60. Global COX-2 Selective NSAIDs Sales (K Units) by Application (2021–2026)

Table 61. Global COX-2 Selective NSAIDs Sales (K Units) by Application (2027–2032)

Table 62. Global COX-2 Selective NSAIDs Sales Market Share by Application (2021–2026)

Table 63. Global COX-2 Selective NSAIDs Sales Market Share by Application (2027–2032)

Table 64. Global COX-2 Selective NSAIDs Revenue (US$ Million) by Application (2021–2026)

Table 65. Global COX-2 Selective NSAIDs Revenue (US$ Million) by Application (2027–2032)

Table 66. Global COX-2 Selective NSAIDs Revenue Market Share by Application (2021–2026)

Table 67. Global COX-2 Selective NSAIDs Revenue Market Share by Application (2027–2032)

Table 68. Global COX-2 Selective NSAIDs Price (US$/Unit) by Application (2021–2026)

Table 69. Global COX-2 Selective NSAIDs Price (US$/Unit) by Application (2027–2032)

Table 70. Pfizer Company Information

Table 71. Pfizer Description and Business Overview

Table 72. Pfizer COX-2 Selective NSAIDs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 73. Pfizer COX-2 Selective NSAIDs Product

Table 74. Pfizer Recent Developments/Updates

Table 75. Teva Company Information

Table 76. Teva Description and Business Overview

Table 77. Teva COX-2 Selective NSAIDs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 78. Teva COX-2 Selective NSAIDs Product

Table 79. Teva Recent Developments/Updates

Table 80. Mylan Company Information

Table 81. Mylan Description and Business Overview

Table 82. Mylan COX-2 Selective NSAIDs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 83. Mylan COX-2 Selective NSAIDs Product

Table 84. Mylan Recent Developments/Updates

Table 85. Apotex Company Information

Table 86. Apotex Description and Business Overview

Table 87. Apotex COX-2 Selective NSAIDs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 88. Apotex COX-2 Selective NSAIDs Product

Table 89. Apotex Recent Developments/Updates

Table 90. Lupin Company Information

Table 91. Lupin Description and Business Overview

Table 92. Lupin COX-2 Selective NSAIDs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 93. Lupin COX-2 Selective NSAIDs Product

Table 94. Lupin Recent Developments/Updates

Table 95. Jiangsu Hengrui Medicine Company Information

Table 96. Jiangsu Hengrui Medicine Description and Business Overview

Table 97. Jiangsu Hengrui Medicine COX-2 Selective NSAIDs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 98. Jiangsu Hengrui Medicine COX-2 Selective NSAIDs Product

Table 99. Jiangsu Hengrui Medicine Recent Developments/Updates

Table 100. Merck Company Information

Table 101. Merck Description and Business Overview

Table 102. Merck COX-2 Selective NSAIDs Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 103. Merck COX-2 Selective NSAIDs Product

Table 104. Merck Recent Developments/Updates

Table 105. Key Raw Materials Lists

Table 106. Raw Materials Key Suppliers Lists

Table 107. COX-2 Selective NSAIDs Distributors List

Table 108. COX-2 Selective NSAIDs Customers List

Table 109. COX-2 Selective NSAIDs Market Trends

Table 110. COX-2 Selective NSAIDs Market Drivers

Table 111. COX-2 Selective NSAIDs Market Challenges

Table 112. COX-2 Selective NSAIDs Market Restraints

Table 113. Research Programs/Design for This Report

Table 114. Key Data Information from Secondary Sources

Table 115. Key Data Information from Primary Sources

Table 116. Authors List of This Report

List of Figures

Figure 1. Product Picture of COX-2 Selective NSAIDs

Figure 2. Global COX-2 Selective NSAIDs Market Value by Type (US$ Million), 2021–2032

Figure 3. Global COX-2 Selective NSAIDs Market Share by Type: 2025 & 2032

Figure 4. Celecoxib Product Picture

Figure 5. Rofecoxib Product Picture

Figure 6. Valdecoxib Product Picture

Figure 7. Etoricoxib Product Picture

Figure 8. Global COX-2 Selective NSAIDs Market Value by Application (US$ Million), 2021–2032

Figure 9. Global COX-2 Selective NSAIDs Market Share by Application: 2025 & 2032

Figure 10. Hospital

Figure 11. Clinic

Figure 12. Other

Figure 13. Global COX-2 Selective NSAIDs Revenue, (US$ Million), 2021 vs 2025 vs 2032

Figure 14. Global COX-2 Selective NSAIDs Market Size (US$ Million), 2021–2032

Figure 15. Global COX-2 Selective NSAIDs Sales (K Units), 2021–2032

Figure 16. Global COX-2 Selective NSAIDs Average Price (US$/Unit), 2021–2032

Figure 17. COX-2 Selective NSAIDs Report Years Considered

Figure 18. COX-2 Selective NSAIDs Sales Share by Manufacturers in 2025

Figure 19. Global COX-2 Selective NSAIDs Revenue Share by Manufacturers in 2025

Figure 20. Top 5 and Top 10 Global COX-2 Selective NSAIDs Players: Market Share by Revenue in COX-2 Selective NSAIDs in 2025

Figure 21. COX-2 Selective NSAIDs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025

Figure 22. Global COX-2 Selective NSAIDs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Figure 23. North America COX-2 Selective NSAIDs Sales Market Share by Country (2021–2032)

Figure 24. North America COX-2 Selective NSAIDs Revenue Market Share by Country (2021–2032)

Figure 25. United States COX-2 Selective NSAIDs Revenue Growth Rate (US$ Million), 2021–2032

Figure 26. Canada COX-2 Selective NSAIDs Revenue Growth Rate (US$ Million), 2021–2032

Figure 27. Europe COX-2 Selective NSAIDs Sales Market Share by Country (2021–2032)

Figure 28. Europe COX-2 Selective NSAIDs Revenue Market Share by Country (2021–2032)

Figure 29. Germany COX-2 Selective NSAIDs Revenue Growth Rate (US$ Million), 2021–2032

Figure 30. France COX-2 Selective NSAIDs Revenue Growth Rate (US$ Million), 2021–2032

Figure 31. U.K. COX-2 Selective NSAIDs Revenue Growth Rate (US$ Million), 2021–2032

Figure 32. Italy COX-2 Selective NSAIDs Revenue Growth Rate (US$ Million), 2021–2032

Figure 33. Russia COX-2 Selective NSAIDs Revenue Growth Rate (US$ Million), 2021–2032

Figure 34. Asia Pacific COX-2 Selective NSAIDs Sales Market Share by Region (2021–2032)

Figure 35. Asia Pacific COX-2 Selective NSAIDs Revenue Market Share by Region (2021–2032)

Figure 36. China COX-2 Selective NSAIDs Revenue Growth Rate (US$ Million), 2021–2032

Figure 37. Japan COX-2 Selective NSAIDs Revenue Growth Rate (US$ Million), 2021–2032

Figure 38. South Korea COX-2 Selective NSAIDs Revenue Growth Rate (US$ Million), 2021–2032

Figure 39. India COX-2 Selective NSAIDs Revenue Growth Rate (US$ Million), 2021–2032

Figure 40. Australia COX-2 Selective NSAIDs Revenue Growth Rate (US$ Million), 2021–2032

Figure 41. China Taiwan COX-2 Selective NSAIDs Revenue Growth Rate (US$ Million), 2021–2032

Figure 42. Southeast Asia COX-2 Selective NSAIDs Revenue Growth Rate (US$ Million), 2021–2032

Figure 43. Latin America COX-2 Selective NSAIDs Sales Market Share by Country (2021–2032)

Figure 44. Latin America COX-2 Selective NSAIDs Revenue Market Share by Country (2021–2032)

Figure 45. Mexico COX-2 Selective NSAIDs Revenue Growth Rate (US$ Million), 2021–2032

Figure 46. Brazil COX-2 Selective NSAIDs Revenue Growth Rate (US$ Million), 2021–2032

Figure 47. Argentina COX-2 Selective NSAIDs Revenue Growth Rate (US$ Million), 2021–2032

Figure 48. Colombia COX-2 Selective NSAIDs Revenue Growth Rate (US$ Million), 2021–2032

Figure 49. Middle East and Africa COX-2 Selective NSAIDs Sales Market Share by Country (2021–2032)

Figure 50. Middle East and Africa COX-2 Selective NSAIDs Revenue Market Share by Country (2021–2032)

Figure 51. Turkey COX-2 Selective NSAIDs Revenue Growth Rate (US$ Million), 2021–2032

Figure 52. Saudi Arabia COX-2 Selective NSAIDs Revenue Growth Rate (US$ Million), 2021–2032

Figure 53. UAE COX-2 Selective NSAIDs Revenue Growth Rate (US$ Million), 2021–2032

Figure 54. Global Sales Market Share of COX-2 Selective NSAIDs by Type (2021–2032)

Figure 55. Global Revenue Market Share of COX-2 Selective NSAIDs by Type (2021–2032)

Figure 56. Global COX-2 Selective NSAIDs Price (US$/Unit) by Type (2021–2032)

Figure 57. Global Sales Market Share of COX-2 Selective NSAIDs by Application (2021–2032)

Figure 58. Global Revenue Market Share of COX-2 Selective NSAIDs by Application (2021–2032)

Figure 59. Global COX-2 Selective NSAIDs Price (US$/Unit) by Application (2021–2032)

Figure 60. COX-2 Selective NSAIDs Value Chain

Figure 61. Channels of Distribution (Direct Vs Distribution)

Figure 62. Bottom-up and Top-down Approaches for This Report

Figure 63. Data Triangulation

Figure 64. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions